Dr. Reddy's Laboratories heads into today's June 17 earnings release with the same structural tension that has defined this entire preview cycle — but the borrow market has tightened sharply since the June 13 article, adding a new layer to an already charged setup.
The headline development since the last preview is in availability, which has fallen back to 41.6% from 86% on June 11. That reversal is dramatic. Just days ago, the lending pool appeared to be absorbing the short build comfortably; now availability has retightened toward the lower end of its recent range, with the 52-week trough sitting at 16.8%. Cost to borrow has also reaccelerated, climbing to 1.52% — up 70% on the week and more than double where it stood a month ago. The short position itself held essentially flat over the past two sessions at 22.2 million shares, following the 13% weekly jump into June 11. The ORTEX short score ticked up to 59.4, its highest reading of the full cycle. Together, these moves describe a borrow market that had briefly relaxed and has now re-tightened as the print arrives.
Options traders are the one signal pointing in a different direction. The put/call ratio has risen to 0.20 — about 1.8 standard deviations above its 20-day average of 0.17 — which is a meaningfully more defensive posture than this stock has shown for most of 2026. But in absolute terms, a PCR of 0.20 remains low. Call open interest still dominates the options book by a wide margin. This is not the profile of a market bracing for a bad print; it is the profile of a market that has added modest hedges while the short book has done the heavier lifting on the bearish side.
The analyst picture offers little fresh resolution. HSBC upgraded the stock to Buy from Hold in June 2025, lifting its target to $16.90 — still well above the current $13.30. The broader consensus from Barclays has consistently carried an Overweight rating, though those notes are dated and should be treated as background context rather than live guidance. Prior recent notes flagged regulatory scrutiny around manufacturing compliance as the key operational overhang, and that concern has not resolved publicly ahead of today's release.
Today's print will test whether the sustained short build — now 66% larger than a month ago and still holding near its cycle peak — reflects genuine visibility into a deteriorating quarter, or whether the reporting numbers challenge a position that has grown large enough to become its own risk.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
